Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Patterns of Care Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia: A Retrospective Study across Diverse US Practices

Tarun Bhagnani, Michael Roth, Kristen M. O'Dwyer, Julie Wolfson, Indrani Chatterjee, Arun Prashar, Ravi Potluri, Eros Papademetriou, Robert Paglia, David Robert Freyer

Blood (2023) 142 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2023-189553

Published: 2023

Journal Articles

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

B. Douglas Smith, Curtis A Lachowiez, Alexander Joseph Ambinder, Gary Binder, Anne Angiolillo, Assaf Vestin, Robert Paglia, Ravi Potluri, Eros Papademetriou, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 971.

https://doi.org/10.1182/blood-2023-173033

Published: 2023

Journal Articles

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Lona Gaugler, Sara Vergara, Ying Qiu, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk

Blood (2023) 142 (Supplement 1): 550.

https://doi.org/10.1182/blood-2023-173442

Published: 2023

Journal Articles

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Tim Werwath, Zhuoer Xie, Eric Padron, David A Sallman

Blood (2023) 142 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2023-180797

Published: 2023

Journal Articles

Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice

Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Clara Chen

Blood (2021) 138 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2021-148044

Published: 2021

Journal Articles

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Gaetano Bonifacio, Clara Chen

Blood (2021) 138 (Supplement 1): 277.

https://doi.org/10.1182/blood-2021-147926

Published: 2021

Journal Articles

Economic Burden of Hospitalizations for Patients with Newly Diagnosed Acute Myeloid Leukemia in Remission in the United States: Retrospective Analysis of an Administrative Claims Database

Clara Chen, Eros Papademetriou, Zephirin Kiendrebeogo, Ravi Potluri

Blood (2021) 138 (Supplement 1): 4976.

https://doi.org/10.1182/blood-2021-147909

Published: 2021

Journal Articles

The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) Database

Clara Chen, David Rotter, Zephirin Kiendrebeogo, Ravi Potluri

Blood (2021) 138 (Supplement 1): 4139.

https://doi.org/10.1182/blood-2021-147979

Published: 2021

Journal Articles

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Angela Dispenzieri, MD, Jeff Zonder, MD, James Hoffman, MD, Sandy W. Wong, MD, Michaela Liedtke, MD, Rafat Abonour, MD, Anita D'Souza, MBBS, Charlene Lee, MSc, Sandhya Nair, PhD MSc, Ravi Potluri, PGDM, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Annette Lam, MSc, Maneesha Mehra, MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140405

Published: 2020

Journal Articles

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Rafael Fonseca, MD, Saad Z. Usmani, MD, Maneesha Mehra, Mary Slavcev, Jon Ukropec, PhD, Annette Lam, Ravi Potluri

Blood (2018) 132 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2018-99-113125

Published: 2018

Journal Articles

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

Ajai Chari, MD, Maneesha Mehra, Mary Slavcev, Annette Lam, Ravi Potluri, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2018-99-113176

Published: 2018

Journal Articles

Utilization of Hypomethylating Agents and Associated Outcomes in Elderly Acute Myeloid Leukemia (AML) Patients: A Population Based Study

Maneesha Mehra, Jimmy He, Ravi Potluri, Christina Loefgren, MD PhD

Blood (2017) 130 (Supplement 1): 2157.

https://doi.org/10.1182/blood.V130.Suppl_1.2157.2157

Published: 2017

Journal Articles

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Jon Ukropec, Ravi Potluri, Anandaroop Dasgupta

Blood (2017) 130 (Supplement 1): 3093.

https://doi.org/10.1182/blood.V130.Suppl_1.3093.3093

Published: 2017

Journal Articles

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Ravi Potluri, Anandaroop Dasgupta

Blood (2017) 130 (Supplement 1): 3094.

https://doi.org/10.1182/blood.V130.Suppl_1.3094.3094

Published: 2017

Journal Articles

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Clara Chen, PhD BS, MS, Ravi Potluri, Hemanth Kanakamedala, Eros Papademetriou, Christopher A. Yasenchak, MD, Sandip Ranjan, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 3127.

https://doi.org/10.1182/blood.V130.Suppl_1.3127.3127

Published: 2017

Journal Articles

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Ravi Potluri, Hemanth Kanakamedala, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Sandip Ranjan, Eros Papademetriou, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 1844.

https://doi.org/10.1182/blood.V130.Suppl_1.1844.1844

Published: 2017

Journal Articles

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Ravi Potluri, Hitesh Bhandari, Sandip Ranjan, Clara Chen, PhD MS

Blood (2016) 128 (22): 2363.

https://doi.org/10.1182/blood.V128.22.2363.2363

Published: 2016

Journal Articles

Evaluation of Cardiovascular Comorbidities Among Patients with Multiple Myeloma in the United States

Daniel J. Lenihan, MD, Ravi Potluri, Hitesh Bhandari, Sandip Ranjan, Clara Chen, PhD MS

Blood (2016) 128 (22): 4794.

https://doi.org/10.1182/blood.V128.22.4794.4794

Published: 2016

Journal Articles

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

Maneesha Mehra, Ravi Potluri, Jianming He, Aleksandra Rizo, Suneel Mundle, Jacqueline Bussolari

Blood (2016) 128 (22): 5974.

https://doi.org/10.1182/blood.V128.22.5974.5974

Published: 2016

Journal Articles

Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases

Maneesha Mehra, Ravi Potluri, Jianming He, Grace Wang, Suneel Mundle, Jacqueline Bussolari

Blood (2016) 128 (22): 4769.

https://doi.org/10.1182/blood.V128.22.4769.4769

Published: 2016

NARROW

Patterns of Care Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia: A Retrospective Study across Diverse US Practices

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Economic Burden of Hospitalizations for Patients with Newly Diagnosed Acute Myeloid Leukemia in Remission in the United States: Retrospective Analysis of an Administrative Claims Database

The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) Database

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma

Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment

Utilization of Hypomethylating Agents and Associated Outcomes in Elderly Acute Myeloid Leukemia (AML) Patients: A Population Based Study

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Evaluation of Cardiovascular Comorbidities Among Patients with Multiple Myeloma in the United States

Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database

Characterization of Disease, Treatment Patterns, and Outcomes of Patients with Myelofibrosis: Analysis of 2 United States Commercial Claims Databases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only